New pill combo could shrink lung tumors before surgery
NCT ID NCT06268210
First seen Feb 12, 2026 · Last updated Jun 21, 2026 · Updated 18 times
Summary
This study tests a targeted cancer pill called lazertinib, given alone or with chemotherapy, before surgery for a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 160 adults with early to mid-stage disease will receive the treatment for three cycles before surgery, then continue lazertinib for three years after. The goal is to see if the treatment shrinks tumors enough to improve surgical outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lazertinib (a targeted cancer pill) with or without chemotherapy (pemetrexed and carboplatin)
What this could lead to
If successful, this could lead to a new treatment option that shrinks EGFR-mutant lung tumors before surgery, potentially improving long-term outcomes.
What could go wrong
This is a Phase II trial with only 160 participants, so results are preliminary. The treatment may not work better than current options, and side effects from the drugs could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.